<DOC>
	<DOCNO>NCT03007693</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability JNJ-61393215 multiple consecutive dose administration characterize pharmacokinetics ( PK ) JNJ-61393215 plasma multiple consecutive dose administration .</brief_summary>
	<brief_title>A Study Investigate Safety Tolerability , Pharmacokinetics Pharmacodynamics JNJ 61393215 Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Healthy male participant 18 55 year age , inclusive Participants must body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive ( BMI = weight/height square ) Participant must healthy basis physical examination , medical history , vital sign , 12lead ECG [ incl . QTcF less equal [ &lt; = ] 450 millisecond ( msec ) males ] perform screen admission clinical unit . Minor abnormality electrocardiogram ( ECG ) , consider clinical significance investigator , acceptable . The presence Left Bundle Branch Block ( LBBB ) , AV Block ( second degree high ) , permanent pacemaker implantable cardioverter defibrillator [ ICD ] lead exclusion Participants must healthy basis clinical laboratory test perform screen . If result serum chemistry panel , hematology , urinalysis outside normal reference range , Participant may include investigator judge abnormality clinically significant . This determination must record Participant 's source document initial investigator A man sexually active woman childbearing potential vasectomy must agree use barrier method contraception e.g. , either condom spermicidal foam/gel/film/cream/suppository study minimum 1 spermatogenesis cycle ( define approximately 90 day ) receive last dose study drug . All men must also donate sperm study 3 month receive last dose study drug . In addition , female partner also use highly effective method contraception least duration . Examples highly effective contraceptive include implantable progestogenonly hormone contraception associate inhibition ovulation ; intrauterine device ( IUD ) ; intrauterine hormonereleasing system ( IUS ) ; vasectomize partner ; sexual abstinence ( sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study drug . The reliability sexual abstinence need evaluate relation duration study prefer usual lifestyle participant . ) , combine ( estrogen progestogencontaining ) hormonal contraception associate inhibition ovulation : oral , intravaginal , transdermal ; progestogenonly hormone contraception associate inhibition ovulation : oral injectable . Participants must willing adhere prohibition restriction specify protocol Participant history current liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , psychiatric , metabolic disturbance , inflammatory illness illness , though minor deviation , consider clinical significance investigator Janssen Safety Responsible Physician , acceptable Current past history psychiatric disorder classify accord Diagnostic Statistical Manual Mental DisordersIV ( DSMIV ) DSMV , exclusion anxiety disorder ( i.e. , panic disorder without agoraphobia , social anxiety disorder , generalize anxiety disorder ) Participant liver function test ( include alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , gammaglutamyltransferase [ gGT ] , alkaline phosphatase [ ALP bilirubin ] screen exceed upper limit normal Participant estimate glomerular filtration rate ( eGFR ) &lt; 60 milliliter per minute ( mL/min ) /1.73m^2 screening ( provided local laboratory ) Participant heart rate &lt; 50 beat per minute ( bpm ) &gt; 100 bpm systolic blood pressure great equal ( &gt; = ) 150 millimeter mercury ( mmHg ) screen admission clinical unit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>